| Name | Title | Contact Details |
|---|
The Siegfried Group is a Philadelphia, PA-based company in the Business Services sector.
NCD is dedicated to improving lives by driving better health, providing an exceptional experience, and Spreading the Smile. As the costs of dental and vision insurance continue to increase across the country, our mission is to provide comprehensive dental and vision care thats accessible, quick to obtain, and simple to use. Whether youre uninsured or under-insured, NCD has a plan that fits your dental and vision needs.
At Prosperity Bank, we believe in a community banking philosophy where personal relationships and great experiences go hand-in-hand. We provide convenient technology options that our customers expect – all backed by the highest level of security. At every touch point, youll find knowledgeable associates ready to serve our customers with accuracy and a smile time and time again. Prosperity provides personal banking services and investments to consumers and small to medium sized businesses throughout Texas and Oklahoma. Founded in 1983, Prosperity ranks among the top 100 U.S. banks in assets. Member FDIC. Equal Housing Lender.
Koto Studio is a creative agency based in London, incorporated in 2014. The company specializes in bridging the gap between design education and professional practice, serving as a digital hub for brand education. They offer a collection of e-books and resources aimed at enhancing brand understanding and development. Koto Studio focuses on designing meaningful and scalable motion systems that enhance branding by guiding attention and building memory. The studio provides brand and digital work, collaborating with various companies, particularly in the gaming industry. They create comprehensive branding experiences that shape how audiences feel and engage with brands. Notable projects include a campaign for Microsoft celebrating its 50th anniversary, showcasing their ability to work with impactful clients across different sectors. Koto Studio is committed to innovation and social responsibility, reflecting awareness of broader social and environmental issues in their branding strategies.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.